Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246480 | 1.00 | NR1H2 (0.41) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL6977617 | 0.88 | MEN1 (0.39) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL5186931 | 0.88 | MEN1 (0.39) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL426434 | 0.88 | NR1H2 (0.39) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL6976635 | 0.87 | HPGD (0.42) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL427722 | 0.85 | EPHX1 (0.38) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL447284 | 0.85 | EPHX1 (0.38) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL6217654 | 0.85 | HPGD (0.40) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL5304979 | 0.83 | RECQL (0.39) | NR1H2HPGDMEN1ALDH1A1MAPT | |
| SCHEMBL15076438 | 0.82 | NR1H2 (0.46) | NR1H2HPGDMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799674-B1 | NEW PIPERIDINE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-20070173532-A1 | New Piperidine Antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173532-A1 | New Piperidine Antibiotics | OPRM1, SIGMAR1, CBR3 | NR1H2 1573/4885HPGD 3726/4885MEN1 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.